CA2399550A1 - Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation - Google Patents

Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation Download PDF

Info

Publication number
CA2399550A1
CA2399550A1 CA002399550A CA2399550A CA2399550A1 CA 2399550 A1 CA2399550 A1 CA 2399550A1 CA 002399550 A CA002399550 A CA 002399550A CA 2399550 A CA2399550 A CA 2399550A CA 2399550 A1 CA2399550 A1 CA 2399550A1
Authority
CA
Canada
Prior art keywords
nucleic acid
subject
immunomodulatory nucleic
pyrimidine
inflammatory bowel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002399550A
Other languages
French (fr)
Inventor
Eyal Raz
Daniel Rachmilewitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tel Aviv Sourasky Medical Center
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2399550A1 publication Critical patent/CA2399550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the metho d comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.

Description

METHOD

Claims (46)

What is claimed is:
1. A method for ameliorating gastrointestinal inflammation in a subject comprising:
administering to a subject suffering from gastrointestinal inflammation a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3', said administering being in an amount effective to ameliorate a symptom of gastrointestinal inflammation in the subject;
wherein gastrointestinal inflammation is ameliorated in the subject.
2. The method of claim 1, wherein the immunomodulatory nucleic acid comprises the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3'.
3. The method of claim 1, wherein the immunomodulatory nucleic acid molecule comprises a CpG motif selected from the group consisting of:
a) 5'-Purine-TCG-Pyrimidine-Pyrimidine-3;
b) 5'-[TCG]n3', where n is any integer that is 1 or greater;
c) 5'-Purine-Purine-CG-Pyrimidine-Pyrimidine-CG-3'; and d) 5'-Purine-TCG-Pyrimidine-Pyrimidine-CG-3'
4. The method of claim 1, wherein the immunomodulatory nucleic acid molecule is selected from the group consisting of an immunostimulatory oligodeoxyribonucleotide (ISS-ODN); an isolated bacterial genomic DNA and plasmid DNA comprising an immunomodulatory nucleic acid sequence.
5. The method of claim 1, wherein the immunomodulatory nucleic acid molecule comprises a sequence selected from the group consisting of: AACGCC, AACGCT, AACGTC, AACGTT, AGCGCC, AGCGCT, AGCGTC, AGCGTT, GACGCC, GACGCT, GACGTC, GACGTT, GGCGCC, GGCGCT, GGCGTC, GGCGTT, ATCGCC, ATCGCT, ATCGTC, ATCGTT, GTCGCC, GTCGCT, GTCGTC, GTCGTT, TCGTCG, TCGTCGTCG, AACGCCCG, AACGCTCG, AACGTCCG, AACGTTCG, AGCGCCCG, AGCGCTCG, AGCGTCCG, AGCGTTCG, GACGCCCG, GACGCTCG, GACGTCCG, GACGTTCG, GGCGCCCG, GGCGCTCG, GGCGTCCG, GGCGTTCG, ATCGCCCG, ATCGCTCG, ATCGTCCG, ATCGTTCG, GTCGCCCG, GTCGCTCG, GTCGTCCG, and GTCGTTCG.
6. The method of claim 4, wherein the immunomodulatory nucleic acid molecule comprises at least one sequence selected from the group consisting of AACGTT, aacgttcg, aacgtt, gtcgtt, and tcgtcg.
7. The method of claim 4, wherein the immunomodulatory nucleic acid molecule comprises at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ ID NO:11).
8. The method of claim 1, wherein the immunomodulatory nucleic acid is administered via a gastroenteral route.
9. The method of claim 1, wherein the gastroenteral route is oral, intranasal, intragastric or rectal
10. The method of claim 1, wherein the immunomodulatory nucleic acid is administered by a systemic route.
11. The method of claim 10, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.
12. The method of claim 1, wherein the immunomodulatory nucleic acid is administered by a mucosal route.
13. The method of claim 1, wherein the gastrointestinal inflammation is chronic gastrointestinal inflammation.
14. The method of claim 13, wherein the chronic gastrointestinal inflammation is caused by inflammatory bowel disease.
15. The method of claim 14, wherein the inflammatory bowel disease is ulcerative colitis.
16. The method of claim 14, wherein the inflammatory bowel disease is Crohn's disease.
17. The method of claim 14, wherein the immunomodulatory nucleic acid is administered in conjunction with a steroid or an antibody directed against tumor necrosis factor-.alpha. (TNF-.alpha.).
18. The method of claim 1, wherein the gastrointestinal inflammation is acute gastrointestinal inflammation.
19. A method for ameliorating inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3', said administering being in an amount effective to ameliorate a symptom of inflammatory bowel disease in the subject;
wherein inflammatory bowel disease is ameliorated in the subject.
20. The method of claim 19, wherein said administering is by an intragastric route.
21. The method of claim 19, wherein said administering is by a subcutaneous route.
22. A method for ameliorating inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEA ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ m NO:11), said administering being in an amount effective to ameliorate a symptom of inflammatory bowel disease in the subject;
23. A method for reducing inflammation caused by a gastrointestinal inflammatory disease in a subject, the method comprising:
administering to a subject suffering from gastrointestinal inflammatory disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-CpG-3', said administering being in an amount effective to reduce inflammation caused by gastrointestinal inflammatory disease in the subject;
wherein inflammation caused by gastrointestinal inflammatory disease is reduced in the subject.
24. The method of claim 23, wherein the immunomodulatory nucleic acid comprises the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3'.
25. The method of claim 23, wherein the immunomodulatory nucleic acid molecule comprises a CpG motif selected from the group consisting of:
a) 5'-Purine-TCG-Pyrimidine-Pyrimidine-3 ;
b) 5'-[TCG]n-3', where n is any integer that is 1 or greater;
c) 5'-Purine-Purine-CG-Pyrimidine-Pyrimidine-CG-3'; and d) 5'-Purine-TCG-Pyrimidine-Pyrimidine-CG-3'
26. The method of claim 23, wherein the immunomodulatory nucleic acid molecule is selected from the group consisting of an immunostimulatory oligodeoxyribonucleotide (ISS-ODN); an isolated, detoxified bacterial polynucleotide; bacterial genomic DNA;
and a plasmid DNA comprising an immunomodulatory nucleic acid.
27. The method of claim 23, wherein the immunomodulatory nucleic acid molecule comprises a sequence selected from the group consisting of AACGCC, AACGCT, AACGTC, AACGTT, AGCGCC, AGCGCT, AGCGTC, AGCGTT, GACGCC, GACGCT, GACGTC, GACGTT, GGCGCC, GGCGCT, GGCGTC, GGCGTT, ATCGCC, ATCGCT, ATCGTC, ATCGTT, GTCGCC, GTCGCT, GTCGTC, GTCGTT, TCGTCG, TCGTCGTCG, AACGCCCG, AACGCTCG, AACGTCCG, AACGTTCG, AGCGCCCG, AGCGCTCG, AGCGTCCG, AGCGTTCG, GACGCCCG, GACGCTCG, GACGTCCG, GACGTTCG, GGCGCCCG, GGCGCTCG, GGCGTCCG, GGCGTTCG, ATCGCCCG, ATCGCTCG, ATCGTCCG, ATCGTTCG, GTCGCCCG, GTCGCTCG, GTCGTCCG, and GTCGTTCG.
28. The method of claim 23, wherein the immunomodulatory nucleic acid molecule comprises the sequence at least one sequence selected from the group consisting of aacgtt, aacgttcg, aacgtt, gtcgtt, and tcgtcg.
29. The method of claim 23, wherein the immunomodulatory nucleic acid comprises at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID
NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID
NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO: 10), and tgaaacgttcgcctgtcgttga (SEQ ID
NO:11).
30. The method of claim 23, wherein the immunomodulatory nucleic acid is administered via a gastroenteral route.
31. The method of claim 30, wherein the gastroenteral route is oral, intranasal, intragastric or rectal.
32. The method of claim 23, wherein the immunomodulatory nucleic acid is administered by a systemic route.
33. The method of claim 32, wherein the systemic route is intradermal, intramuscular, subcutaneous or intravenous.
34. The method of claim 23 wherein the immunomodulatory nucleic acid is administered by a mucosal route.
35. The method of claim 23, wherein the gastrointestinal inflammation is chronic gastrointestinal inflammation.
36. The method of claim 33, wherein the chronic gastrointestinal inflammation is caused by inflammatory bowel disease.
37. The method of claim 36, wherein the immunomodulatory nucleic acid is administered in conjunction with a steroid or an antibody directed against tumor necrosis factor-.alpha. (TNF-.alpha.).
38. The method of claim 35, wherein the chronic gastrointestinal inflammatory disease is ulcerative colitis.
39. The method of claim 35, wherein the chronic gastrointestinal inflammatory disease is Crohn's disease.
40. A method for reducing inflammation caused by inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising the sequence 5'-Purine-Purine-[C]-[G]-Pyrimidine-Pyrimidine-3', said administering being in an amount effective to reduce inflammation caused by inflammatory bowel disease in the subject;
wherein inflammation caused by inflammatory bowel disease is reduced in the subject.
41. The method of claim 40, wherein said administering is by an intragastric route.
42. The method of claim 40, wherein said administering is by a subcutaneous route.
43. The method of claim 40, wherein the inflammatory bowel disease is ulcerative colitis.
44. The method of claim 40, wherein reduction of inflammation of ulcerative colitis further decreases the risk of colonic carcinoma.
45. The method of claim 43, wherein the inflammatory bowel disease is Crohn's disease.
46. A method for reducing inflammation of inflammatory bowel disease in a subject comprising:
administering to a subject suffering from inflammatory bowel disease a formulation comprising an immunomodulatory nucleic acid to the subject, the immunomodulatory nucleic acid comprising at least one sequence selected from the group consisting of tgactgtgaacgttcgagatga (SEQ ID NO:1), tgactgtgaacgttagagatga (SEQ ID NO:5), tgactgtggtcgttagagatga (SEQ ID NO:9), tcgtcgtcgtcgtcgtcgtcgt (SEQ ID NO:10), and tgaaacgttcgcctgtcgttga (SEQ ID NO:11), said administering being in an amount effective to reduce inflammation in the subject;
wherein inflammation caused by inflammatory bowel disease is reduced in the subject.
CA002399550A 2000-02-23 2001-02-22 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation Abandoned CA2399550A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18425600P 2000-02-23 2000-02-23
US60/184,256 2000-02-23
PCT/US2001/006034 WO2001062207A2 (en) 2000-02-23 2001-02-22 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation

Publications (1)

Publication Number Publication Date
CA2399550A1 true CA2399550A1 (en) 2001-08-30

Family

ID=22676177

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002399550A Abandoned CA2399550A1 (en) 2000-02-23 2001-02-22 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation

Country Status (6)

Country Link
US (2) US6613751B2 (en)
EP (1) EP1259264A4 (en)
AU (3) AU2001241751B2 (en)
CA (1) CA2399550A1 (en)
IL (1) IL151345A0 (en)
WO (1) WO2001062207A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0879284B1 (en) * 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1733735B1 (en) * 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
ATE419869T1 (en) 1999-08-19 2009-01-15 Dynavax Tech Corp METHOD FOR MODULATING AN IMMUNE RESPONSE USING IMMUNSTIMULATIVE SEQUENCES AND COMPOSITIONS THEREOF
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
ATE378348T1 (en) * 2000-01-14 2007-11-15 Us Health OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
EP1292331A2 (en) * 2000-06-07 2003-03-19 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030133988A1 (en) * 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
ATE554169T1 (en) * 2001-11-02 2012-05-15 Giuliani Int Ltd SMAD7 INHIBITORS FOR THE TREATMENT OF CNS DISEASES
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
JP4689268B2 (en) * 2002-06-14 2011-05-25 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Methods for treating and preventing colitis for IL-13 and NK-T cells
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
NZ538628A (en) * 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7758876B2 (en) * 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7956043B2 (en) * 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
EP1575977B1 (en) 2002-12-23 2009-09-09 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
CN101454451A (en) 2003-10-30 2009-06-10 科勒制药有限公司 C-class oligonucleotide analogs with enhanced immunostimulatory potency
JP4817599B2 (en) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 Immune activity enhancer and method for enhancing immune activity using the same
WO2005072290A2 (en) * 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
US20080008741A1 (en) * 2004-02-03 2008-01-10 Eyal Raz Methods of Treating Irritable Bowel Syndrome
US7560436B2 (en) 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
CA2600036A1 (en) 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1877074B1 (en) 2005-04-15 2013-03-27 The Government of the United States of America, as represented by the Secretary of Health and Human Services Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells
AU2006335883B2 (en) * 2006-01-20 2011-04-28 Morinaga Milk Industry Co., Ltd. Pharmaceutical composition, food or drink, or feed for intestinal disease
CN105853394A (en) * 2006-03-30 2016-08-17 恩根尼公司 Non-viral compositions and methods for transfecting gut cells in vivo
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
WO2008131074A1 (en) * 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
CN101820908A (en) 2007-10-09 2010-09-01 科利制药公司 The immune stimulatory oligonucleotide analogs that comprises modified sugar moieties
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
AR091569A1 (en) * 2012-06-28 2015-02-11 Intervet Int Bv TOLL TYPE RECEIVERS
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
EP3223803A1 (en) * 2014-11-24 2017-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
MA41271A (en) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc METHODS OF USE OF OLIGONUCLEOTIDES ANTISENS TARGETING SMAD7
US20200281950A1 (en) * 2015-12-28 2020-09-10 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AU6280596A (en) * 1995-06-15 1997-01-15 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
ES2284247T3 (en) 1998-04-03 2007-11-01 University Of Iowa Research Foundation METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS.
US20030013668A1 (en) * 1998-07-07 2003-01-16 Dange Veerapanane Ph.D Antisense oligonucleotides targeted to il-15
AP1775A (en) 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
MXPA02003059A (en) 1999-09-27 2002-09-30 Univ Iowa Res Found Methods related to immunostimulatory nucleic acid induced interferon.

Also Published As

Publication number Publication date
WO2001062207A2 (en) 2001-08-30
US7485627B2 (en) 2009-02-03
EP1259264A4 (en) 2005-08-31
US20030176389A1 (en) 2003-09-18
US6613751B2 (en) 2003-09-02
WO2001062207A3 (en) 2001-12-20
IL151345A0 (en) 2003-04-10
US20020042387A1 (en) 2002-04-11
EP1259264A2 (en) 2002-11-27
AU2005237172A1 (en) 2005-12-15
AU2001241751B2 (en) 2005-09-01
AU4175101A (en) 2001-09-03

Similar Documents

Publication Publication Date Title
CA2399550A1 (en) Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
JP2002500159A5 (en)
O'hagan The intestinal uptake of particles and the implications for drug and antigen delivery.
HK1191567A1 (en) Multivalent pneumococcal polysaccharide protein conjugate composition
MX2013006539A (en) Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions.
MX2019008863A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition.
MY159984A (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
PL1631264T3 (en) Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid
MX2009006548A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition.
MX2009013949A (en) Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates.
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
EA200801367A1 (en) VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
WO2004053056A3 (en) Nanoparticle-based vaccine delivery system containing adjuvant
MX2009007144A (en) Antifolate agent combinations in the treatment of cancer.
MX2009011312A (en) Vaccination regimen for b-cell vaccines.
Kim et al. Development of lymphocytic gastritis with recurrent Helicobacter pylori infection.
Kim et al. Enhanced Cancer Immunotherapy by In situ Nanomicelle-generating Dissolving Microneedles
Tran et al. Clinical Characteristics, Endoscopic Images and Histopathology of Colorectal Cancer at 108 Military Central Hospital from 2018 to 2019.
Arfi et al. Carcinome cuniculatum: une tumeur orale inhabituelle
Skwarczynski et al. Polymerized Amino Acids as a Self-Adjuvanting Delivery System for Vaccine against Group A Streptococcus
Khaki Najafabadi et al. Magnetic Drug Delivery of Xanthohumol to Adipocytes Using Ultrasmall Superparamagnetic Iron Oxide Nanoparticles.
Rustamov Elaboration of optimal Helicobacter pylori eradication regimens for patients with duodenal ulcer
Herrero et al. Síndrome alcohólico fetal. Criterios diagnósticos. Hallazgos en 13 casos estudiados
Park et al. Enhanced mucosal and systemic immune responses by mucosally administered hepatitis B surface antigen: effects of vaccine delivery vehicles and adjuvants
ICHINOKAWA et al. A case of a rectal carcinoid tumor with solitary recurrence to the right lateral lymph node performed trans-sacral extirpation after systemic chemotherapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued